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In the HAART era, the incidence of HIV-associated
Kaposi's sarcoma (KS) has declined precipitously for
countries with ready access to anti-retrovirals. Patients
with newly diagnosed KS typically have low CD4+counts
and high HIV viral loads (VLs). Several recently published
reports (NEJM 2007;357:1352–3, NEJM 2008;358:535–
6, AIDS 2008;22:551–2) suggest that patients with KS
may require treatment despite effective HAART and that
KS may progress even in the setting of suppressed HIV VLs
and adequate CD4+ counts.
To investigate this further, we examined the demographic
and HIV-related clinical data of 91 KS patients attending
our HIV outpatient clinic between 1996 and 2008. Twenty
of the 91 patients (22%) had either newly diagnosed KS
or persistent or progressive disease despite CD4+ counts
>300 cells/μL and undetectable HIV VLs. Nineteen of
these 20 patients were males. The median age was 43 years
(range 25 to 59), the median time since onset of HIV
infection was 156 months (range 24 to 276) and the
median duration of HAART was 60 months (range 12 to
144). Nine (45%) patients had a KS stage of T0S0, five
(25%) had T1S0, three (15%) had T0S1, three (15%) had
T1S1; no patient had KS visceral involvement. All 20
patients received specific anti-KS treatment in addition to
HAART including liposomal doxorubicin (65%), paclit-
axel (15%), radiation (20%) and novel clinical agents
(25%). After a median follow up of 52 months (range 6 to
120), eight (40%) had complete regression of KS, six
(30%) had partial regression, one (5%) had stable disease
and five (25%) had KS progression. In this retrospective
analysis, a substantial proportion of KS patients had
undetectable HIV VLs and CD4+counts greater than the
level typically associated with opportunistic infections
and required systemic anti-ks therapy. This raises impor-
tant questions regarding the mechanisms of KS progres-
sion and the management of KS in such patients.
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